Table 1 Clinical and preclinical studies about the association between gut microbiome and the host response to immune checkpoint inhibitors sorted by the category of bacteria
From: The role of the bacterial microbiome in the treatment of cancer
Gut microbiome categories | Mice model, or patients | Impacts | References |
|---|---|---|---|
Bacteroidetes Bacteroides B. fragilis B. thetaiotaomicron B. caccae Bacteroides thetaiotamicron Bacteroidales | Antibiotic-treated or germ-free mice with MCA205 sarcomas receive Anti-CTLA-4(Ipilimumab) therapy | Improved response and reduced colitis | Vetizou et al. (2015) [41] |
MM patients receive Anti-CTLA-4(Ipilimumab) therapy | Reduced the risk of ICIs induced colitis | Dubin et al. (2016) [14] | |
Adult MM patients receive Ipilimumab, Nivolumab Ipilimumab plus nivolumab, pembrolizumab (Anti-CTLA-4 or Anti–PD-1 or combination of Anti-CTLA-4 and Anti–PD-1 therapy) | Predicted effective therapeutic response | Frankel et al. (2017) [21] | |
MM patients receive Anti-CTLA-4(Ipilimumab) therapy | Bacteroides decreased therapeutic response and decrease risk of ICIs-induced colitis | Chaput et al. (2017) [13] | |
MM patients, germ-free mice with injection of BP melanoma cell receive Anti–PD-1 therapy | Bacteroidales decreased response, and attenuate systemic and antitumor immunity | Gopalakrishnan et al. (2018) [20] | |
Bifidobacterium B. pseudolongum B. longum | Melanoma mice with distinct commensal microbiota receive Anti–PD-L1 therapy | Delayed melanoma growth, and enhanced CD8 + T cell priming and accumulation in the tumor microenvironment | Sivan et al. (2015) [22] |
MM patients receive Anti–PD-1 therapy | Improved therapeutic response, enhanced tumor control, and improved T cell response. | Matson et al. (2018) [19] | |
germ-free or specific-pathogen-free mice with injection of MC38 colorectal cancer cells receive anti CTLA-4 treatment | B. pseudolongum (belongs to B. pseudolongum) enhanced immunotherapy response through production of the metabolite inosine | Mager et al. (2020) [42] | |
Faecalibacterium and other Firmicutes Clostridiales Faecalibacterium Faecalibacterium prausnitzii | MM patients , germ-free mice with injection of BP melanoma cell receive Anti–PD-1 therapy | Clostridiales Faecalibacterium and Ruminococcaceae Improved response, enhanced systemic and antitumor immunity | Gopalakrishnan et al. (2018) [20] |
Adult MM patients receive Ipilimumab, Nivolumab Ipilimumab plus nivolumab, pembrolizumab (Anti-CTLA-4 or Anti–PD-1 or combination of Anti-CTLA-4 and Anti–PD-1 therapy) | Predicted effective therapeutic response | Frankel et al. (2017) [21] | |
MM patients receive Anti-CTLA-4(Ipilimumab) therapy | Faecalibacterium and other Firmicutes Improved therapeutic response and higher risk of ICIs induced colitis | Chaput et al. (2017) [13] | |
Ruminococcaceae | MM patients, germ-free mice with injection of BP melanoma cell receive Anti–PD-1 therapy | Ruminococcaceae Improved response, and enhanced cancer immunity | Gopalakrishnan et al. (2018) [20] |
Collinsella aerofaciens | MM patients receive Anti–PD-1 therapy | Improved therapeutic response, enhanced tumor control, and improved T cell response. | Matson et al. (2018) |
Enterococcus faecium | MM patients receive Anti–PD-1 therapy | Improved therapeutic response, enhanced cancer immunity, and improved T cell response. | Matson et al. (2018) |
Olsenella species | germ-free or specific-pathogen-free mice with injection of MC38 colorectal cancer cells receive anti CTLA-4 treatment | Improved therapeutic response, enhanced cancer immunity, and improved T cell response. | Mager et al. (2020) [42] |
Lactobacillus johnsonii, | germ-free or specific-pathogen-free mice with injection of MC38 colorectal cancer cells receive anti CTLA-4 treatment | Improved therapeutic response, enhanced cancer immunity, and improved T cell response. | Mager et al. (2020) [42] |
Holdemania filiformis | Adult MM patients receive Ipilimumab, Nivolumab Ipilimumab plus nivolumab, pembrolizumab (Anti-CTLA-4 or Anti–PD-1 or combination of Anti-CTLA-4 and Anti–PD-1 therapy) | Predicted effective therapeutic response | Frankel et al. (2017) [21] |
Dorea formicogenerans | Adult MM patients receive Ipilimumab, Nivolumab Ipilimumab plus nivolumab, pembrolizumab (Anti-CTLA-4 or Anti–PD-1 or combination of Anti-CTLA-4 and Anti–PD-1 therapy) | Dorea formicogenerans enriched only in patients who accepted pembrolizumab and predicted effective therapeutic response | Frankel et al. (2017) [21] |
Akkermansia muciniphil | NSCLC and RCC patients receive Anti-PD-L1 and Anti–PD-1 | Improved therapeutic response | Routy et al. (2018) [18] |
Alistipes | NSCLC and RCC patients receive Anti-PD-L1 and Anti–PD-1 | Improved therapeutic response | Routy et al. (2018 )[18] |